|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RBBP6 |
Gene summary for RBBP6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RBBP6 | Gene ID | 5930 |
| Gene name | RB binding protein 6, ubiquitin ligase | |
| Gene Alias | MY038 | |
| Cytomap | 16p12.1 | |
| Gene Type | protein-coding | GO ID | GO:0001701 | UniProtAcc | Q7Z6E9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5930 | RBBP6 | cSCC_p4 | Human | Skin | cSCC | 1.07e-04 | 2.90e-02 | -0.2022 |
| 5930 | RBBP6 | cSCC_p8 | Human | Skin | cSCC | 1.46e-10 | 1.42e-01 | -0.1971 |
| 5930 | RBBP6 | cSCC_p9 | Human | Skin | cSCC | 9.75e-07 | 9.52e-02 | -0.1991 |
| 5930 | RBBP6 | Adj_PTCwithHT_6 | Human | Thyroid | HT | 3.04e-15 | -7.53e-01 | 0.02 |
| 5930 | RBBP6 | Adj_PTCwithHT_8 | Human | Thyroid | HT | 3.19e-05 | -4.99e-01 | 0.0267 |
| 5930 | RBBP6 | PTCwithHT_1 | Human | Thyroid | HT | 7.53e-03 | -6.20e-01 | 0.0238 |
| 5930 | RBBP6 | PTCwithHT_6 | Human | Thyroid | HT | 1.78e-18 | -7.70e-01 | 0.02 |
| 5930 | RBBP6 | PTCwithHT_8 | Human | Thyroid | HT | 1.55e-13 | -7.50e-01 | 0.0351 |
| 5930 | RBBP6 | PTCwithoutHT_2 | Human | Thyroid | PTC | 7.63e-07 | -5.12e-01 | 0.0419 |
| 5930 | RBBP6 | PTCwithoutHT_4_2 | Human | Thyroid | PTC | 3.54e-02 | -7.70e-01 | 0.0455 |
| 5930 | RBBP6 | PTCwithoutHT_7 | Human | Thyroid | PTC | 2.12e-05 | -7.56e-01 | 0.0381 |
| 5930 | RBBP6 | male-WTA | Human | Thyroid | PTC | 1.40e-53 | -3.42e-01 | 0.1037 |
| 5930 | RBBP6 | nodule-WTA | Human | Thyroid | goiters | 1.96e-02 | -5.14e-01 | 0.0534 |
| 5930 | RBBP6 | PTC01 | Human | Thyroid | PTC | 8.43e-07 | -2.19e-01 | 0.1899 |
| 5930 | RBBP6 | PTC03 | Human | Thyroid | PTC | 6.09e-08 | -3.02e-01 | 0.1784 |
| 5930 | RBBP6 | PTC04 | Human | Thyroid | PTC | 1.50e-12 | -1.77e-01 | 0.1927 |
| 5930 | RBBP6 | PTC05 | Human | Thyroid | PTC | 1.87e-09 | 1.77e-01 | 0.2065 |
| 5930 | RBBP6 | PTC06 | Human | Thyroid | PTC | 8.69e-08 | 3.87e-01 | 0.2057 |
| 5930 | RBBP6 | PTC07 | Human | Thyroid | PTC | 1.22e-14 | 1.27e-01 | 0.2044 |
| 5930 | RBBP6 | ATC08 | Human | Thyroid | ATC | 1.50e-04 | -6.31e-01 | 0.0541 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000170119 | Esophagus | ESCC | in utero embryonic development | 243/8552 | 367/18723 | 1.00e-15 | 6.86e-14 | 243 |
| GO:00062604 | Esophagus | ESCC | DNA replication | 181/8552 | 260/18723 | 3.55e-15 | 2.05e-13 | 181 |
| GO:00062754 | Esophagus | ESCC | regulation of DNA replication | 73/8552 | 107/18723 | 1.97e-06 | 2.28e-05 | 73 |
| GO:00352647 | Esophagus | ESCC | multicellular organism growth | 80/8552 | 132/18723 | 3.84e-04 | 2.22e-03 | 80 |
| GO:00485687 | Esophagus | ESCC | embryonic organ development | 228/8552 | 427/18723 | 7.28e-04 | 3.79e-03 | 228 |
| GO:00017015 | Liver | Cirrhotic | in utero embryonic development | 134/4634 | 367/18723 | 2.78e-07 | 6.86e-06 | 134 |
| GO:003526411 | Liver | Cirrhotic | multicellular organism growth | 47/4634 | 132/18723 | 3.40e-03 | 1.89e-02 | 47 |
| GO:000170111 | Liver | HCC | in utero embryonic development | 204/7958 | 367/18723 | 2.44e-07 | 4.30e-06 | 204 |
| GO:00062601 | Liver | HCC | DNA replication | 146/7958 | 260/18723 | 5.68e-06 | 7.02e-05 | 146 |
| GO:00062751 | Liver | HCC | regulation of DNA replication | 60/7958 | 107/18723 | 3.15e-03 | 1.46e-02 | 60 |
| GO:003526421 | Liver | HCC | multicellular organism growth | 70/7958 | 132/18723 | 9.29e-03 | 3.57e-02 | 70 |
| GO:00017016 | Lung | IAC | in utero embryonic development | 68/2061 | 367/18723 | 1.12e-05 | 3.45e-04 | 68 |
| GO:00352644 | Lung | IAC | multicellular organism growth | 25/2061 | 132/18723 | 4.69e-03 | 3.68e-02 | 25 |
| GO:00485684 | Lung | IAC | embryonic organ development | 64/2061 | 427/18723 | 6.46e-03 | 4.59e-02 | 64 |
| GO:00062603 | Oral cavity | OSCC | DNA replication | 159/7305 | 260/18723 | 3.25e-13 | 1.59e-11 | 159 |
| GO:000170116 | Oral cavity | OSCC | in utero embryonic development | 207/7305 | 367/18723 | 7.92e-12 | 2.95e-10 | 207 |
| GO:00062753 | Oral cavity | OSCC | regulation of DNA replication | 62/7305 | 107/18723 | 5.49e-05 | 4.54e-04 | 62 |
| GO:00352646 | Oral cavity | OSCC | multicellular organism growth | 65/7305 | 132/18723 | 1.06e-02 | 3.60e-02 | 65 |
| GO:000170117 | Oral cavity | LP | in utero embryonic development | 142/4623 | 367/18723 | 1.48e-09 | 6.75e-08 | 142 |
| GO:000626011 | Oral cavity | LP | DNA replication | 97/4623 | 260/18723 | 3.67e-06 | 7.75e-05 | 97 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RBBP6 | SNV | Missense_Mutation | c.1990N>A | p.Asp664Asn | p.D664N | Q7Z6E9 | protein_coding | deleterious_low_confidence(0.05) | probably_damaging(0.996) | TCGA-A7-A26H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD | |
| RBBP6 | SNV | Missense_Mutation | c.2220N>C | p.Lys740Asn | p.K740N | Q7Z6E9 | protein_coding | deleterious_low_confidence(0) | benign(0.091) | TCGA-A7-A26H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD | |
| RBBP6 | SNV | Missense_Mutation | rs750648345 | c.4101N>G | p.Ser1367Arg | p.S1367R | Q7Z6E9 | protein_coding | deleterious_low_confidence(0) | benign(0.021) | TCGA-A8-A075-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | epirubicin | CR |
| RBBP6 | SNV | Missense_Mutation | c.4496N>G | p.Asp1499Gly | p.D1499G | Q7Z6E9 | protein_coding | deleterious_low_confidence(0) | benign(0.086) | TCGA-A8-A09W-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| RBBP6 | SNV | Missense_Mutation | rs774633010 | c.1327N>T | p.Ala443Ser | p.A443S | Q7Z6E9 | protein_coding | tolerated_low_confidence(0.17) | benign(0.062) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| RBBP6 | SNV | Missense_Mutation | c.457N>C | p.Gly153Arg | p.G153R | Q7Z6E9 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.998) | TCGA-AN-A0FV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| RBBP6 | SNV | Missense_Mutation | c.2257N>A | p.Tyr753Asn | p.Y753N | Q7Z6E9 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.942) | TCGA-AN-A0XN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| RBBP6 | SNV | Missense_Mutation | c.3235C>G | p.Gln1079Glu | p.Q1079E | Q7Z6E9 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.931) | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| RBBP6 | SNV | Missense_Mutation | c.1622G>C | p.Arg541Thr | p.R541T | Q7Z6E9 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.991) | TCGA-BH-A209-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RBBP6 | SNV | Missense_Mutation | c.307N>C | p.Asp103His | p.D103H | Q7Z6E9 | protein_coding | deleterious_low_confidence(0.03) | probably_damaging(0.927) | TCGA-C8-A12K-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |